Skip to main content

After a Heart Attack, a 90-Day High-Risk Period

About a quarter of patients are hospitalized again within three months, according to new, real-world data shared at the American Heart Association Scientific Sessions 2020.

model of a heart with EKG waves

Heart attack survivors are at risk of another cardiovascular complication, but when are they most vulnerable?

The first 30 days after a heart attack is often thought to be the highest-risk period, but new data suggests that danger zone extends even longer – to 90 days after the initial event, according to an analysis of a U.S. Medicare claims database of more than 125,000 patients presented by CSL Behring at the American Heart Association’s annual Scientific Sessions.

Data from the real-world study found that nearly a quarter of heart attack survivors had to be re-admitted to the hospital within three months, with an increase in the number of heart problems, stroke or health issues that require inpatient care observed between the 30- and 90-day time period.

“This research suggests we may need to redefine the high-risk period for heart attack survivors from one month to three months after the initial event,” said Larry Deckelbaum, CSL Behring Vice President, Research and Development, Cardiovascular and Metabolic Therapeutic Area.

CSL Behring released these and additional real world data at this week’s American Heart Association Scientific Sessions, an important annual meeting for cardiovascular research and peer-to-peer sharing. Cardiovascular disease is the leading cause of death globally, with an estimated 800,000 acute myocardial infarctions (heart attacks) occurring each year in the United States alone.

CSL Behring is doing extensive research into cardiovascular disease and its impact on public health, including an ongoing Phase 3 clinical trial. The trial is studying whether a novel therapy can improve outcomes in heart attack survivors in the 90 days that follow the initial event. AEGIS-II, which launched in 2018, will evaluate the efficacy and safety of CSL112 and plans to enroll 17,400 patients in 49 countries.